SEC Filing Summary: Rexahn Pharmaceuticals, Inc. (Form 8-K)
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Rexahn Pharmaceuticals, Inc. on January 21, 2014. The report details the closing of a registered direct offering of common stock and warrants. Note: The input metadata references "Opus Genetics, Inc.," but the filing text explicitly identifies the registrant as Rexahn Pharmaceuticals, Inc.
Key Financial Metrics
The filing reports the following transaction-specific financial data:
- Gross Proceeds: $20,000,001
- Shares Sold: 19,047,620 shares of common stock
- Warrants Issued: Warrants to purchase 4,761,905 shares of common stock
- Warrant Terms: Five-year duration; exercise price of $1.28 per share; ratio of 0.25 warrant per share sold
The filing text does not provide clear values for revenue, profit, cash flow, operating margins, existing debt levels, or general liquidity metrics outside of the proceeds from this specific offering.
Material Changes
The primary material change is the increase in equity capital and the dilution of existing shareholders resulting from the issuance of 19,047,620 new shares and associated warrants. This transaction was previously announced on January 15, 2014, and closed on the date of this report.
Outlook, Risks, and Management Commentary
The filing contains no explicit management commentary regarding future guidance, operational outlook, or specific risk factors beyond the standard disclosure of the capital raise. The proceeds are intended to fund the company's operations, though specific allocation details are not provided in this text.
Key Facts for Investor Verification
- Verify the use of the $20,000,001 in gross proceeds as disclosed in subsequent filings or press releases.
- Confirm the impact of the 19,047,620 new shares and 4,761,905 warrants on the company's fully diluted share count.
- Review the company's cash position and burn rate to assess runway following this capital raise.
- Check for any underwriting fees or transaction costs that may reduce the net proceeds from the gross amount reported.